News | December 14, 2022
Balaxi conducts groundbreaking for its Rs 85 crore Hyderabad manufacturing facility
The investment will enable the company to enter European markets as well as enhance margins in current markets
The investment will enable the company to enter European markets as well as enhance margins in current markets
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company will address the observations within a stipulated timeline working with the regulators
This will be an added advantage for Supriya Lifescience Limited in the European market.
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
This new fund is amongst the largest for the sector in India
Subscribe To Our Newsletter & Stay Updated
